Movement Alert｜Spyre Therapeutics Falls 5.04% in Pre-Market Trading, Director Share Sale Continues to Pressure Stock

Market Focus06-25

On June 25, Spyre Therapeutics fell 5.04% in pre-market trading, trading at $82.44/share, with turnover of $18,000. The stock continues to face selling pressure following a sharp 13%-plus decline in the prior session.

On the news front, a regulatory filing disclosed that director Michael Thomas Henderson sold 20,000 company shares on June 22 for approximately $2 million. Since the disclosure on June 23, the stock has come under sustained pressure, with trading volume in the prior session surging to over 2.9 million shares — more than double the daily average of roughly 1.3 million. For a clinical-stage biotechnology company still operating at a loss with negative earnings per share of -$0.74 as of its most recent quarterly report, insider selling has amplified market concerns about the company's outlook.

Spyre Therapeutics is a preclinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel disease, with a pipeline including extended half-life antibodies targeting α4β7, TL1A, and IL-23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140298473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 16:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140298473","market":"us","top_or_hot":-1,"title":"Movement Alert｜Spyre Therapeutics Falls 5.04% in Pre-Market Trading, Director Share Sale Continues to Pressure Stock","media":"Market Focus","content":"<p><p>On June 25, Spyre Therapeutics fell 5.04% in pre-market trading, trading at $82.44/share, with turnover of $18,000. The stock continues to face selling pressure following a sharp 13%-plus decline in the prior session.</p><p>On the news front, a regulatory filing disclosed that director Michael Thomas Henderson sold 20,000 company shares on June 22 for approximately $2 million. Since the disclosure on June 23, the stock has come under sustained pressure, with trading volume in the prior session surging to over 2.9 million shares — more than double the daily average of roughly 1.3 million. For a clinical-stage biotechnology company still operating at a loss with negative earnings per share of -$0.74 as of its most recent quarterly report, insider selling has amplified market concerns about the company's outlook.</p><p>Spyre Therapeutics is a preclinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel disease, with a pipeline including extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Spyre Therapeutics Falls 5.04% in Pre-Market Trading, Director Share Sale Continues to Pressure Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Spyre Therapeutics Falls 5.04% in Pre-Market Trading, Director Share Sale Continues to Pressure Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 16:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Spyre Therapeutics fell 5.04% in pre-market trading, trading at $82.44/share, with turnover of $18,000. The stock continues to face selling pressure following a sharp 13%-plus decline in the prior session.</p><p>On the news front, a regulatory filing disclosed that director Michael Thomas Henderson sold 20,000 company shares on June 22 for approximately $2 million. Since the disclosure on June 23, the stock has come under sustained pressure, with trading volume in the prior session surging to over 2.9 million shares — more than double the daily average of roughly 1.3 million. For a clinical-stage biotechnology company still operating at a loss with negative earnings per share of -$0.74 as of its most recent quarterly report, insider selling has amplified market concerns about the company's outlook.</p><p>Spyre Therapeutics is a preclinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel disease, with a pipeline including extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRE","symbol_name":"SPYRE THERAPEUTICS INC","start_time":0,"source_url":"","article_id":"1140298473","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140298473","pubTimestamp":1782375544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Spyre Therapeutics fell 5.04% in pre-market trading, trading at $82.44/share, with turnover of $18,000. The stock continues to face selling pressure following a sharp 13%-plus decline in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRE":"SPYRE THERAPEUTICS INC"},"translate_title":"动向提示|Spyre Therapeutics盘前跌5.04%董事售股继续承压股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":1},"content_text":"On June 25, Spyre Therapeutics fell 5.04% in pre-market trading, trading at $82.44/share, with turnover of $18,000. The stock continues to face selling pressure following a sharp 13%-plus decline in the prior session.On the news front, a regulatory filing disclosed that director Michael Thomas Henderson sold 20,000 company shares on June 22 for approximately $2 million. Since the disclosure on June 23, the stock has come under sustained pressure, with trading volume in the prior session surging to over 2.9 million shares — more than double the daily average of roughly 1.3 million. For a clinical-stage biotechnology company still operating at a loss with negative earnings per share of -$0.74 as of its most recent quarterly report, insider selling has amplified market concerns about the company's outlook.Spyre Therapeutics is a preclinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel disease, with a pipeline including extended half-life antibodies targeting α4β7, TL1A, and IL-23.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140298473","isCrawlerRequest":true}